Trial Profile

A Phase 2 Study of Magrolimab Combination Therapy in Patients With Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 25 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Magrolimab (Primary) ; Paclitaxel (Primary) ; Paclitaxel (Primary) ; Sacituzumab govitecan (Primary)
Indications Advanced breast cancer; Triple negative breast cancer
Focus Adverse reactions; Therapeutic Use
Acronyms ELEVATE TNBC
Sponsors Gilead Sciences

Most Recent Events

23 Oct 2024 Status changed from active, no longer recruiting to discontinued.
19 Sep 2024 Planned End Date changed from 1 Jan 2025 to 1 Oct 2024.
19 Sep 2024 Planned primary completion date changed from 1 Aug 2024 to 1 Oct 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com